Navigation Links
Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy
Date:10/20/2014

LONDON, October 20, 2014 /PRNewswire/ --

Norgine B.V. today announced that the Phase II study of its novel, low volume bowel preparation, NER1006, presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG), Philadelphia, PA, has met its primary efficacy end point of stool weight and co-primary endpoint of cleansing success. The study demonstrated high quality bowel cleansing efficacy with NER1006 vs. MOVIPREP® in screening colonoscopy patients.[1]

(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

The Phase II open-label, randomised study (OPT, n=240) investigated the pharmacodynamics (stool weight), clinical efficacy and tolerability of dose and taste-optimised low-volume PEG-based formulations (NER1006), after split dosing, compared with MOVIPREP®.[1] Results demonstrate that NER1006 achieved high quality bowel cleansing in screening colonoscopy patients, comparable with MOVIPREP®. Cleansing success rates were 90-100%.[1] Stool output was consistently higher with NER1006, and safety and tolerability profiles between treatments were comparable.[1] In addition, most subjects in the NER1006 arms reached clear effluent.[1]

"Effective bowel cleansing is vital to delivering a successful colonoscopy procedure. This Phase II study confirms that NER1006, a low volume preparation, is preferential for some patients and improves tolerability. We are hoping that the Phase III programme will further show the efficacy and tolerability of NER1006," commented Donna McVey, Chief Development Officer, Norgine.

Norgine has now enrolled the first patient into the first study of its Phase III programme, NOCT, a US study. The Phase III programme consists of three clinical trials: NOCT is a multicentre, randomised, parallel-group clinical trial that is expected to enrol 540 patients across two arms, MORA and DAYB are European studies to further investigate the bowel cleansing efficacy, compliance, safety, patient acceptability and tolerability of NER1006.

--------------------------------------------

References 

1. Halphen M, et al. Pharmacodynamic and clinical evaluation of low-volume polyethylene glycol based bowel cleansing solutions (NER1006) using split dosing in healthy and screening colonoscopy subjects. ACG 2014 abstract #P330 

 

See full release on http://www.norgine.com

Charlotte Andrews: Tel - +44-(0)1895-453669

Peter Martin: Tel- +44-(0)1895-453744

 

Job code: GL/COR/1014/0024

October 2014


'/>"/>
SOURCE Norgine B.V
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results
2. Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
3. Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
4. SALVAT Announces Positive Top-line Results from Two Phase III Studies of its Novel Otic Antibiotic/Steroid Combination Solution in the Treatment of AOMT with Tympanostomy Tubes
5. Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
6. Glenmarks TRPA1 Antagonist GRC 17536 Shows Positive Data in a Proof of Concept Study
7. ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial
8. Aratana Therapeutics Reports Positive Effectiveness Data from Pilot Field Study of Bupivacaine Extended-Release Injectable Suspension (AT-003)
9. Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular Carcinoma
10. Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
11. Fractyl Labs Announces Positive Clinical Data for First Procedural Therapy to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2018)... ... 07, 2018 , ... Cardiologist Ernst von Schwarz, MD says that women can ... or ignored completely by their doctors. “This can be especially dangerous in younger women ... educate themselves on symptoms that are unique to women so they may become better ...
(Date:12/6/2018)... ... December 06, 2018 , ... Last year, 172 children deaths ... of those children had not gotten the vaccine. Vaccination is the first step in ... shots reduce the severity of the illness if infected. Along with getting vaccinated, people ...
(Date:12/6/2018)... , ... December 06, 2018 , ... ... and with it, more answers for the millions of Americans and people worldwide ... other available treatment facilities, the renowned Alternative to Meds Center utilizes the tenets ...
Breaking Medicine Technology:
(Date:12/13/2018)... , ... December 13, 2018 , ... ... to appear more modern and approachable in their community. Delia Associates created a ... provide treatment for those dealing with substance abuse in the greater Hunterdon County ...
(Date:12/13/2018)... ... December 13, 2018 , ... Allegheny General ... Westfield Memorial Hospital, all part of Allegheny Health Network (AHN), have been recognized ... (CHIME). , Most Wired® is the industry-leading survey on IT adoption and innovation ...
(Date:12/10/2018)... ... December 10, 2018 , ... In the aftermath of ... has more recently been reinforced by the Me Too movement. To redress the balance, ... their inner Man free and become the Men they were always meant to be ...
(Date:12/10/2018)... ... December 10, 2018 , ... ... Room and Florida Hospital Wesley Chapel recently received the 2018 Press Ganey Guardian ... experience. The award for both emergency and inpatient services is measured through random, ...
(Date:12/8/2018)... ... December 08, 2018 , ... The Human Animal Bond ... for pet parents, has become an official supporter of HABRI and its research ... the advancement of human-animal bond research, whiskerDocs is demonstrating its commitment to the ...
Breaking Medicine News(10 mins):